Literature DB >> 22500369

Tumor necrosis factor-alfa and interleukin-4 in cerbrospinal fluid and plasma in different clinical forms of multiple sclerosis.

Dragana Obradović1, Milena Kataranovski, Evica Dincić, Slobodan Obradović, Miodrag Colić.   

Abstract

BACKGROUND/AIM: Multiple sclerosis (MS) is an immune-mediated central nervous system disease characterized by inflammation, demyelination and axonal degeneration. Cytokines are proven mediators of immunological process in MS. The aim of this study was to investigate whether there is a difference in the production of the tumor necrosis factor alpha (TNF-alpha) and interleukin-4 (IL-4) in cerebrospinal fluid (CSF) and plasma in the MS patients and the controls (other neurological non-inflammatory diseases) and to determine a possible difference in these cytokines in plasma and CSF in different clinical forms of MS.
METHODS: This study involved 60 consecutive MS patients--48 patients with relapsing-remitting MS (RRMS) and 12 patients with secondary progressive MS (SPMS). The control group consisted of 20, age and sex matched, non-immunological, neurological patients. According to the clinical presentation of MS at the time of this investigation, 34 (56.7%) patients had relapse (RRMS), 14 (23.3%) were in remission (RRMS), while the rest of the patients, 12 (20.0%), were SPMS. TNF-alpha and IL-4 concentrations were measured in the same time in CSF and plasma in the MS patients and the controls. Extended disability status score (EDSS), albumin ratio and IgG index were determined in all MS patients.
RESULTS: The MS patients had significantly higher CSF and plasma levels of TNF-alpha than the controls (p < 0.001 for both samples). IL-4 CSF levels were significantly lower in the MS patients than in the controls (p < 0.001), however plasma levels were similar. The patients in relapse (RRMS) and with progressive disease (SPMS) had higher concentrations of CSF TNF-alpha levels than the patients in remission (p < 0.001). IL-4 CSF levels in relapse (RRMS) and SPMS groups were lower than in the patients in remission. The patients in remission had an unmeasurable plasma TNF-alpha level and the patients with SPMS had significantly lower IL-4 levels in plasma than the patients in relapse and remission (p < 0.001). The only significant correlation between cytokine level with either EDSS, or albumin ratio, or IgG index, was found between CSF TNF-alpha levels and albumin ratio in the patients with relapse (R square = 0.431, p < 0.001).
CONCLUSION: According to the obtained data MS relapse was characterized by high concentrations of TNF-alpha in CSF and plasma and low concentrations of IL-4 in CSF. Remission was characterized by high concentrations of IL-4 and low concentrations of TNF-alpha both in CSF and plasma. SPMS was characterized with lower concentrations of TNF-alpha and IL-4 compared to relapse, both in CSF and plasma.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22500369

Source DB:  PubMed          Journal:  Vojnosanit Pregl        ISSN: 0042-8450            Impact factor:   0.168


  8 in total

1.  Effects of low-dose-gamma rays on the immune system of different animal models of disease.

Authors:  Noriko Shimura; Shuji Kojima
Journal:  Dose Response       Date:  2014-04-23       Impact factor: 2.658

2.  Lower serum levels of Th2-related chemokine CCL22 in women patients with multiple sclerosis: a comparison between patients and healthy women.

Authors:  A Jafarzadeh; H A Ebrahimi; S Bagherzadeh; F Zarkesh; F Iranmanesh; A Najafzadeh; A Khosravimashizi; M Nemati; A Sabahi; H Hajghani; H Daneshvar; M M Mohammadi
Journal:  Inflammation       Date:  2014-04       Impact factor: 4.092

3.  Cytokine Profile in Patients with Progressive Multiple Sclerosis and Its Association with Disease Progression and Disability.

Authors:  Ana Paula Kallaur; Sayonara Rangel Oliveira; Andréa Name Colado Simão; Daniela Frizon Alfieri; Tamires Flauzino; Josiane Lopes; Wildea Lice de Carvalho Jennings Pereira; Caio de Meleck Proença; Sueli Donizete Borelli; Damacio Ramón Kaimen-Maciel; Michael Maes; Edna Maria Vissoci Reiche
Journal:  Mol Neurobiol       Date:  2016-03-29       Impact factor: 5.590

Review 4.  An evaluation of the recognised systemic inflammatory biomarkers of chronic sub-optimal inflammation provides evidence for inflammageing (IFA) during multiple sclerosis (MS).

Authors:  Christopher Bolton
Journal:  Immun Ageing       Date:  2021-04-14       Impact factor: 6.400

Review 5.  IL-6 and TNF-α responses to acute and regular exercise in adult individuals with multiple sclerosis (MS): a systematic review and meta-analysis.

Authors:  Parnian Shobeiri; Homa Seyedmirzaei; Nastaran Karimi; Fatemeh Rashidi; Antônio L Teixeira; Serge Brand; Dena Sadeghi-Bahmani; Nima Rezaei
Journal:  Eur J Med Res       Date:  2022-09-26       Impact factor: 4.981

6.  Impaired toll-like receptor 8 signaling in multiple sclerosis.

Authors:  Tory P Johnson; Richa Tyagi; Karan Patel; Nicoline Schiess; Peter A Calabresi; Avindra Nath
Journal:  J Neuroinflammation       Date:  2013-06-21       Impact factor: 8.322

7.  Tumor necrosis factor-alpha polymorphism and susceptibility to multiple sclerosis in the Iranian population.

Authors:  Masoomeh Rahmanian; Mohammad Kargar
Journal:  Iran Red Crescent Med J       Date:  2014-12-27       Impact factor: 0.611

Review 8.  Adenosine A2A Receptor Signaling in the Immunopathogenesis of Experimental Autoimmune Encephalomyelitis.

Authors:  Skanda Rajasundaram
Journal:  Front Immunol       Date:  2018-03-06       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.